Letting drug manufacturers “pick and choose” which 340B program requirements they will comply with “could set us on a treacherous path where program participants might disregard
…Note from the Publisher and CEO Ted Slafsky: We are still collecting reaction from our breaking story last night but have plenty of other news and information in today’s issue. Due to the Labor Day holiday, we
…In a major development, the Health Resources and Services Administration (HRSA) has told 340B Report that it is investigating whether recent manufacturer policies to restrict
…After publication, 340B Report received the following comment from Eli Lilly and Co. on its actions that we reported on today:
…Report after report shows 340B is not working for patients and needs reform. We support recent executive action on
Note from the Publisher and CEO Ted Slafsky: Bronwyn Mixter is filling in for Tom Mirga this week. If you have story ideas or tips, feel free to reach her at bronwyn.mixter@340breport.com or 703-403-5926. We’re pleased to include
…Note from the Publisher and CEO: Happy Wednesday. Bronwyn Mixter is filling in for Tom Mirga this week and next week. If you have story ideas or tips, feel free to reach her at bronwyn.mixter@340breport.com or 703-403-5926.
Note from Publisher and CEO Ted Slafsky: We are pleased that Bronwyn Mixter is filling in for Tom Mirga for the next two weeks while Tom takes a late summer break. Bronwyn is a veteran health care reporter who covered
…A Message from Publisher and CEO Ted Slafsky: I hope all is well. For now, we have more requests for 340B Report sponsorships than space available. Fortunately, we are creating a new website and newsletter platform that will accommodate our growing
…Drug manufacturer AstraZeneca today sent letters to 340B covered entities and its wholesale pharmacy contacts telling them that, effective Oct. 1, it
…
×
*Sign up for news summaries and alerts from 340B Report